Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TLX
TLX logo

TLX Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Telix Pharmaceuticals Ltd (TLX) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
9.430
1 Day change
-1.05%
52 Week Range
18.490
Analysis Updated At
2026/05/29
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.

Telix Pharmaceuticals Ltd is not a good buy right now for a beginner long-term investor with $50,000-$100,000 who wants to act immediately. The stock is trading weakly near support with negative momentum, no bullish proprietary signal, no recent news catalyst, and no supportive analyst or trading flow data. I would not buy it now; I would wait for a clearer reversal or stronger fundamental confirmation.

Technical Analysis

TLX is in a short-term bearish setup. The price is 9.48, down 0.63% in regular trading and 1.47% pre-market. MACD histogram is -0.168 and remains below zero, which signals bearish momentum even though the decline is contracting. RSI_6 at 27.658 is oversold-leaning but not giving a strong reversal confirmation. Moving averages are converging, which suggests the trend is undecided, but the stock is still sitting just above S1 at 9.496 and below the pivot at 10.031. The pattern-based estimate also points to near-term downside pressure, with an 80% chance of a -3.5% move next day and -2.26% next week.

Positive Catalysts

  • No recent news was reported in the last week, so there are no event-driven catalysts currently supporting the stock. The only mild positive is that RSI is near oversold territory, and the MACD decline is contracting, which could eventually support a rebound if buying emerges.

Neutral/Negative Catalysts

  • Recent price action is weak, with the stock below the pivot and close to support. Pre-market trading is also negative. There has been no news catalyst in the past week. Hedge funds are neutral and insiders are neutral, so there is no visible accumulation signal. The stock trend model points to downside over the next day and week. AI Stock Picker has no signal today, and SwingMax has no signal recently.

Financial Performance

No usable financial snapshot was provided, so the latest quarter financial performance cannot be assessed from the data given.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target change data was provided, so there is no evidence here of improving Wall Street sentiment. Based on the available information, pros would point to an oversold setup near support, while cons dominate due to weak momentum, no catalyst, and no bullish trading signals.

Wall Street analysts forecast TLX stock price to rise
Analyst Rating
0
Wall Street analysts forecast TLX stock price to rise
Buy
Hold
Sell
0
Current: 9.530
sliders
Low
0
Averages
0
High
0
0
Current: 9.530
sliders
Low
0
Averages
0
High
0
JPMorgan
Overweight
initiated
$23.60
AI Analysis
2026-05-31
New
Reason
JPMorgan
Price Target
$23.60
AI Analysis
2026-05-31
New
initiated
Overweight
Reason
JPMorgan initiated coverage of Telix Pharmaceuticals with an Overweight rating and A$23.60 price target. The firm sees clinical and regulatory catalysts in the near-term that could unlock value, including FDA clearance for TLX-591 to randomized Part 2 and the Zircaix application resubmission, ae well as Pixclara approval into the September 11 action date. Telix is well positioned to benefit from \"structural tailwinds\" in radioligand therapies, the analyst tells investors in a research note.
Citi
Buy
maintain
$22
2026-02-24
Reason
Citi
Price Target
$22
2026-02-24
maintain
Buy
Reason
Citi raised the firm's price target on Telix Pharmaceuticals to $22.50 from $22 and keeps a Buy rating on the shares. The firm updated the company's model post the Q4 report.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for TLX
Unlock Now

People Also Watch